Subscribe
shutterstock_1643880010kate-krav-rude
Kate Krav-Rude / Shutterstock.com
7 May 2020AmericasSarah Morgan

Bausch Health resolves IBS patent litigation

Canada-based  Bausch Health has agreed to settle its dispute with generic maker  Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan (Rifaximin).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Bausch settles $300m antitrust case over diabetes drug price hikes
13 September 2021   Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Big Pharma
Bausch targets India-based firm over IBS drug generic
20 June 2023   Pharma giant claims infringement of two patents | Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Bausch settles $300m antitrust case over diabetes drug price hikes
13 September 2021   Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Big Pharma
Bausch targets India-based firm over IBS drug generic
20 June 2023   Pharma giant claims infringement of two patents | Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details.

More on this story

Big Pharma
Bausch settles $300m antitrust case over diabetes drug price hikes
13 September 2021   Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Americas
Pharma unit could get green light to launch IBS generic
2 August 2022   Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
Big Pharma
Bausch targets India-based firm over IBS drug generic
20 June 2023   Pharma giant claims infringement of two patents | Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York